n South African Journal of Obstetrics and Gynaecology - Product news

Volume 11, Issue 3
  • ISSN : 0038-2329
  • E-ISSN: 2078-5135



Extracted from text ... PRODUCT NEWS ? PRODUCT NEWS Detrol LA/DetrustitolSR reduces urgency, the most bothersome symptom for patients with overactive bladder A Pfizer Inc study showed that Detrol LA (tolterodine tartrate extended release capsules)/Detrusitol SR (tolterodine tartrate sustained release capsules) significantly increases the urgency-free interval (UFI) of patients with overactive bladder (OAB) symptoms compared with patients taking placebo. Results from the multi-centered international study were presented at the International Continence Society meeting in Paris. Study author Vik Khullar, MD, Department of Obstetrics and Gynecology, St Mary's Hospital, London, explained: 'Detrol LA/Detrusitol SR seems to prolong the filling phase, delays sensation of urgency and ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error